To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

Inclusion criteria: * Diagnosis of RA, ≥3 months disease duration; * Participant willing and able to self-inject; * Continuous treatment with 1 or a combination of non-biologic disease modifying antirheumatic drugs (DMARDs) (except leflunomide in combination with methotrexate); * Moderate-to-severely active RA. Exclusion criteria: * Participants \<18 years; * Prior treatment with anti-interleukin 6 (IL-6) or IL-6 receptor (IL-6R) antagonists; * Treatment with tumor necrosis factor (TNF) antagonists; * Treatment with RA-directed biologic agents other than with a TNF-α antagonist mechanism as follows: Anakinra, Abatacept, Rituximab or other cell-depleting agent; * Prior treatment with a Janus kinase inhibitor. The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.